2023
Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center
Basiri M, Ghaffari M, Ruan J, Murugesan V, Kleytman N, Belinsky G, Akhavan A, Lischuk A, Guo L, Klinger K, Mistry P. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center. ELife 2023, 12: e87537. PMID: 37249220, PMCID: PMC10317498, DOI: 10.7554/elife.87537.Peer-Reviewed Original ResearchConceptsEnzyme replacement therapySubstrate reduction therapyAvascular osteonecrosisTertiary referral centerGaucher diseaseReferral centerTreatment initiationGD patientsImiglucerase enzyme replacement therapyResidual disease activityAnti-drug antibodiesYears of treatmentType of therapyRare inborn errorMixed-effects logistic modelGD1 patientsSpleen statusDisease activityClinical outcomesRisk stratificationReplacement therapyIndependent correlatesMultiple therapiesReduction therapyHigh risk
2020
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis
Martinez L, Cords O, Horsburgh C, Andrews J, Consortium P, Acuna-Villaorduna C, Ahuja S, Altet N, Augusto O, Baliashvili D, Basu S, Becerra M, Bonnet M, Boom W, Borgdorff M, Boulahbal F, Carvalho A, Cayla J, Chakhaia T, Chan P, Cohen T, Croda J, Datta S, del Corral H, Denholm J, Dietze R, Dobler C, Donkor S, Egere U, Ellner J, Espinal M, Evans C, Fang C, Fielding K, Fox G, García L, García-Basteiro A, Geis S, Graham S, Grandjean L, Hannoun D, Hatherill M, Hauri A, Hesseling A, Hill P, Huang L, Huerga H, Hussain R, Jarlsberg L, Jones-López E, Kato S, Kato-Maeda M, Kampmann B, Kirchner H, Kritski A, Lange C, Lee C, Lee L, Lee M, Lemos A, Lienhardt C, Ling D, Liu Q, Lo N, Long R, Lopez-Varela E, Lu P, Magee M, Malone L, Mandalakas A, Martinson N, Mazahir R, Murray M, Netto E, Otero L, Parsonnet J, Reingold A, Schaaf H, Seddon J, Sharma S, Singh J, Singh S, Sloot R, Sotgiu G, Stein C, Iqbal N, Triasih R, Trieu L, van der Loeff M, Van der Stuyft P, van Schalkwyk C, Vashishtha R, Verhagen L, Villalba J, Wang J, Whalen C, Yoshiyama T, Zar H, Zellweger J, Zhu L. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. The Lancet 2020, 395: 973-984. PMID: 32199484, PMCID: PMC7289654, DOI: 10.1016/s0140-6736(20)30166-5.Peer-Reviewed Original ResearchConceptsYears of agePreventive therapyIncident tuberculosisTuberculosis infectionHazard ratioTuberculosis casesMixed-effects Poisson regression modelsSystematic reviewFinal analysisClose exposureIncident tuberculosis casesRisk of tuberculosisDevelopment of tuberculosisEMBASE electronic databasesIndividual participant dataPositive resultsPoisson regression modelsWeb of ScienceMixed-effects logistic modelBCG vaccinationCohort studyBaseline visitPrevalent tuberculosisContact investigationProspective study
2018
Comparison of In-Hospital Outcomes of Patients With-Versus-Without Ischemic Cardiomyopathy Undergoing Left Ventricular Assist Device Placement
Abubakar H, Subahi A, Adegbala O, Yassin A, Akintoye E, Abdulrahman A, Ahmed A, Alade A, Pahuja M, Afonso L. Comparison of In-Hospital Outcomes of Patients With-Versus-Without Ischemic Cardiomyopathy Undergoing Left Ventricular Assist Device Placement. The American Journal Of Cardiology 2018, 123: 414-418. PMID: 30545482, DOI: 10.1016/j.amjcard.2018.10.039.Peer-Reviewed Original ResearchConceptsVentricular assist device placementPostoperative myocardial infarctionLength of stayHospital mortalityVascular complicationsLVAD placementMyocardial infarctionEnd pointLeft ventricular assist device placementNationwide Inpatient Sample databaseST-segment myocardial infarctionDevice placementPeriprocedural vascular complicationsHeart failure etiologyIn-Hospital OutcomesPrimary end pointSecondary end pointsClinical end pointsHospital-level characteristicsCost of hospitalizationHemorrhage requiring transfusionMixed-effects logistic modelHospital outcomesFailure etiologyIschemic cardiomyopathyFinancial Implications and Impact of Pre-existing Atrial Fibrillation on In-Hospital Outcomes in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the National Inpatient Database)
Abubakar H, Yassin A, Akintoye E, Bakhit K, Pahuja M, Shokr M, Lieberman R, Afonso L. Financial Implications and Impact of Pre-existing Atrial Fibrillation on In-Hospital Outcomes in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the National Inpatient Database). The American Journal Of Cardiology 2018, 121: 1587-1592. PMID: 29622287, DOI: 10.1016/j.amjcard.2018.02.052.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic Valve StenosisArrhythmias, CardiacAtrial FibrillationCardiac Pacing, ArtificialCardiac TamponadeComorbidityDatabases, FactualFemaleHeart ArrestHeart FailureHospital CostsHospital MortalityHumansLength of StayLinear ModelsLogistic ModelsMaleMyocardial InfarctionPacemaker, ArtificialPericardial EffusionPostoperative ComplicationsPostoperative HemorrhageStrokeTranscatheter Aortic Valve ReplacementUnited StatesConceptsTranscatheter aortic valve implantationPre-existing atrial fibrillationLength of stayPeriprocedural cardiac complicationsAortic valve implantationAtrial fibrillationCost of hospitalizationCardiac complicationsHospital mortalityEnd pointValve implantationLonger hospital LOSUnderwent Transcatheter Aortic Valve ImplantationPre-existing AFHospital LOSIncidence of AFLonger LOSNationwide Inpatient Sample databaseIn-Hospital OutcomesPrimary end pointSecondary end pointsClinical end pointsHospital-level characteristicsMixed-effects logistic modelTAVI patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply